10

Sep2020

Volume 1 Issue 1 Release of PDCI Market Access Insights Journal

PDCI Market Access is pleased to release our premier issue of PDCI Market Access INSIGHTS online journal to our Market Access Toolkit subscribers. The articles in our first issue provide deep dives into: Planning and budgeting PSPs during the pandemic,New data and new perspectives on private insurers and ... Read More

09

Sep2020

Neil Palmer is Guest Editor, Cell & Gene Therapy Insights Spotlight on Market Access

The August 2020 issue of Cell & Gene Therapy Insights, has a focus on Market access: evolving commercialization trends and strategies.  PDCI Market Access’ very own Neil Palmer is featured as a guest editor and the author of the article, Under construction: roadmaps for HTA, pricing and ... Read More

09

Sep2020

Cell & Gene Therapy Insights

Palmer-Cell-and-Gene-Theraoy-InsightsDownload

07

Jul2020

NEW PDCI INFOGRAPHIC: Best Practices for CADTH Request for Reconsideration

PDCI Market Access Inc. is pleased to share its best practices infographic focused on Requesting Reconsideration under the Canadian Agency for Drugs and Technologies in Health (CADTH) Procedures for the Common Drug Review (CDR). While optional and only appropriate in select circumstances, manufacturers should not overlook this potential opportunity ... Read More

20

Jun2020

New Draft PMPRB Guidelines: A High Level Summary

As PDCI announced earlier today, the PMPRB has issued the second draft of the PMPRB Guidelines to support the implementation of Patented Medicines Regulations (Regulations) changes coming unto force on January 1, 2021.  This draft is now available for a 30-day Notice and Comment Period.  Written feedback ... Read More

01

Jun2020

PMPRB Guidelines and Regulations Update

PMPRB Guidelines and Regulations Update As first disclosed by PDCI last week, the PMPRB Board Chair officially confirmed that the amended Patented Medicines Regulations (“Regulations”) will now come into force on January 1, 2021.  These Regulations were published in Canada Gazette II in August 2019 with ... Read More

05

May2020

TargetPharma – CADTH Pharmaceutical Review Update 15

REMINDER: As announced last month, PDCI and its research partners are studying the private payer product listing agreement (PLA) landscape in Canada by surveying pharmaceutical manufacturers and private payers about their ... Read More

16

Apr2020

PDCI Launches 2020 Private Payer PLA Study

PDCI Market Access Inc. (PDCI), in collaboration with Connex Health Consulting, is excited to announce the launch of its 2020 Private Payer Product Listing Agreement (PLA) study! The objective of this research is to share insights about the private payer PLA landscape among pharmaceutical stakeholders ... Read More

06

Apr2020

PDCI Market Access Inc. Welcomes Mark Fleming as a Strategic Advisor

PDCI Market Access Inc. (PDCI), Canada’s leading pricing, reimbursement and health economics consultancy, is pleased to announce its strategic partnership with Mark Fleming.  Mark is joining PDCI as Strategic Advisor supporting PDCI’s pricing, market access and policy research activities.   ... Read More

31

Mar2020

PDCI Acquires Exclusive License for TELUS Health’s Market Access Toolkit Including INSIGHTS Magazine and Census of Insurers

We are excited to announce that PDCI Market Access Inc. (“PDCI”) has entered into an Exclusive License Agreement for the rights to the Market Access Toolkit from TELUS Health Solutions Inc. The Market Access Toolkit has been a critical resource to the pharmaceutical industry for more than 20 years. First developed ... Read More